BACKGROUND: In patients with multiple sclerosis (MS), contrast-enhancing lesions (CELs) on postcontrast MRI are considered markers of the inflammatory responses associated with blood-brain barrier breakdown. Based upon shape, CELs may be defined as nodular (nCEL) or ring (rCEL) lesions. Several short-term studies pointed towards the assumption that rCELs represent areas of a more aggressive inflammatory process. METHODS: In the present long-term (i.e., 2 years) retrospective natural history study, we used monthly imaging to follow rCEL and nCELs evolution in 16 patients with MS during the natural history. New CELs were identified monthly on month 4-9 MRIs, using month 1-3 MRIs to ensure that all CELs were not previously enhancing. Chronic black holes (cBHs) were counted monthly upon CEL disappearance up to the 24th MRI. Generalized estimating equation methods investigated within-patient differences between rCELs and nCELs in volume and likelihood to convert into cBHs. Kaplan-Meier survival curves estimated differences in the length of persistence between cBHs originating from nCELs and cBHs deriving from rCELs. RESULTS: Fifty-two new rCELs and 281 nCELs were identified. rCELs had larger mean (z = 5.06, p < or = 0.0001) volumes than nCELs. The proportion of cBHs from rCELs was similar (z = 1.81, p = 0.0710) to the proportion of cBHs from nCELs. Likewise, the length of persistence of cBHs deriving from rCELs was similar (chi(1)(2) = 2.339, p = 0.1262) to the duration of cBHs from nCELs. CONCLUSIONS: Our data suggest that worse radiologic characteristics associated with the acute phase of ring contrast-enhancing lesions and nodular contrast-enhancing lesions do not necessarily reflect a poorer lesion outcome over time.
BACKGROUND: In patients with multiple sclerosis (MS), contrast-enhancing lesions (CELs) on postcontrast MRI are considered markers of the inflammatory responses associated with blood-brain barrier breakdown. Based upon shape, CELs may be defined as nodular (nCEL) or ring (rCEL) lesions. Several short-term studies pointed towards the assumption that rCELs represent areas of a more aggressive inflammatory process. METHODS: In the present long-term (i.e., 2 years) retrospective natural history study, we used monthly imaging to follow rCEL and nCELs evolution in 16 patients with MS during the natural history. New CELs were identified monthly on month 4-9 MRIs, using month 1-3 MRIs to ensure that all CELs were not previously enhancing. Chronic black holes (cBHs) were counted monthly upon CEL disappearance up to the 24th MRI. Generalized estimating equation methods investigated within-patient differences between rCELs and nCELs in volume and likelihood to convert into cBHs. Kaplan-Meier survival curves estimated differences in the length of persistence between cBHs originating from nCELs and cBHs deriving from rCELs. RESULTS: Fifty-two new rCELs and 281 nCELs were identified. rCELs had larger mean (z = 5.06, p < or = 0.0001) volumes than nCELs. The proportion of cBHs from rCELs was similar (z = 1.81, p = 0.0710) to the proportion of cBHs from nCELs. Likewise, the length of persistence of cBHs deriving from rCELs was similar (chi(1)(2) = 2.339, p = 0.1262) to the duration of cBHs from nCELs. CONCLUSIONS: Our data suggest that worse radiologic characteristics associated with the acute phase of ring contrast-enhancing lesions and nodular contrast-enhancing lesions do not necessarily reflect a poorer lesion outcome over time.
Authors: S Gupta; J M Solomon; T A Tasciyan; M M Cao; R D Stone; J L Ostuni; J M Ohayon; P A Muraro; J A Frank; N D Richert; H F McFarland; F Bagnato Journal: Mult Scler Date: 2005-12 Impact factor: 6.312
Authors: J H van Waesberghe; M A van Walderveen; J A Castelijns; P Scheltens; G J Lycklama à Nijeholt; C H Polman; F Barkhof Journal: AJNR Am J Neuroradiol Date: 1998-04 Impact factor: 3.825
Authors: A Rovira; J Alonso; G Cucurella; C Nos; M Tintoré; S Pedraza; J Rio; X Montalban Journal: AJNR Am J Neuroradiol Date: 1999 Nov-Dec Impact factor: 3.825
Authors: I J van den Elskamp; J Lembcke; V Dattola; K Beckmann; C Pohl; W Hong; R Sandbrink; K Wagner; D L Knol; B Uitdehaag; F Barkhof Journal: Mult Scler Date: 2008-07 Impact factor: 6.312
Authors: A W Chiu; M Ehrmantraut; N D Richert; V N Ikonomidou; S Pellegrini; H F McFarland; J A Frank; F Bagnato Journal: Clin Exp Immunol Date: 2007-07-30 Impact factor: 4.330
Authors: Maria Di Gregorio; Lorenzo Gaetani; Paolo Eusebi; Piero Floridi; Antonella Picchioni; Giovanni Rosi; Andrea Mancini; Chiara Floridi; Francesca Baschieri; Lucia Gentili; Paola Sarchielli; Paolo Calabresi; Massimiliano Di Filippo Journal: J Neurol Date: 2018-01-11 Impact factor: 4.849
Authors: María I Gaitán; Colin D Shea; Iordanis E Evangelou; Roger D Stone; Kaylan M Fenton; Bibiana Bielekova; Luca Massacesi; Daniel S Reich Journal: Ann Neurol Date: 2011-06-27 Impact factor: 10.422
Authors: Bing Yao; Vasiliki N Ikonomidou; Fredric K Cantor; Joan M Ohayon; Jeff Duyn; Francesca Bagnato Journal: J Neuroimaging Date: 2015-02-06 Impact factor: 2.486
Authors: Vasiliki N Ikonomidou; Nancy D Richert; Alexander Vortmeyer; Fernanda Tovar-Moll; Bibiana Bielekova; Natalie E Cook; Jeff H Duyn; Francesca Bagnato Journal: Mult Scler Date: 2013-10 Impact factor: 6.312